8-KRegulation FDExhibits & Filings

BOSTON SCIENTIFIC CORP 8-K Report, Regulation FD Disclosure (Oct 22, 2019)

Filed October 22, 2019For Securities:BSX

Summary

Boston Scientific Corporation (BSX) announced on October 22, 2019, the commencement of a cash tender offer for up to $1.0 billion in aggregate principal amount of its outstanding senior notes. The offer targets specific note series due in 2022, 2023, 2025, and 2028, with interest rates ranging from 3.375% to 4.125%. This move suggests the company is looking to manage its debt structure, potentially refinancing at more favorable terms or reducing overall leverage. Investors should note that the consummation of this tender offer is contingent upon a financing condition, meaning the company must secure the necessary funds. The full terms and conditions are detailed in the offer to purchase document. This action is primarily an operational and financial management decision, and the information provided does not constitute an offer to purchase the securities but rather an announcement of its availability.

Key Highlights

  • 1Boston Scientific (BSX) launched a cash tender offer for up to $1.0 billion of its outstanding senior notes.
  • 2The tender offer includes specific note maturities: 2022, 2023, 2025, and 2028.
  • 3The targeted notes have coupon rates ranging from 3.375% to 4.125%.
  • 4The offer aims to proactively manage the company's debt profile.
  • 5The completion of the tender offer is subject to a financing condition.
  • 6The announcement was made via a press release filed as an exhibit to the 8-K.
  • 7This filing does not constitute an offer to purchase but an informational announcement.

Frequently Asked Questions

Boston Scientific has initiated a cash tender offer to purchase up to $1.0 billion of its outstanding senior notes due in 2022, 2023, 2025, and 2028. This is a common corporate action to manage debt obligations, potentially by refinancing at lower interest rates or altering the company's debt maturity profile.

No, the tender offer is specifically for certain outstanding senior notes, including the 4.125% Senior Notes due 2023, 4.000% Senior Notes due 2028, 3.850% Senior Notes due 2025, and 3.375% Senior Notes due 2022. Other debt instruments may not be affected.

The primary condition mentioned for the consummation of the tender offer is a 'financing condition.' This means Boston Scientific must successfully secure the necessary funding to complete the purchases.

If you hold one of the targeted note series, you may have received an offer to sell your notes back to Boston Scientific for cash. The specifics of the offer, including pricing and deadlines, are detailed in the company's 'offer to purchase' document. If you do not hold these specific notes, this tender offer does not directly impact your holdings.